The Valley Desk

ArticleJournal of comparative effectiveness researchPublished

Healthcare cost comparison between first-line ibrutinib and acalabrutinib in chronic lymphocytic leukemia patients in the Veterans Affairs

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source

Publication record

Type
Article
Venue
Journal of comparative effectiveness research
Published
Subject terms
Humans; Benzamides; Piperidines; Pyrazines; Adenine; Protein Kinase Inhibitors; Retrospective Studies; United States Department of Veterans Affairs; Aged; Aged, 80 and over; Middle Aged; Health Care Costs
PubMed ID
41084890
PubMed Central ID
PMC12580920
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal